Navigation Links
Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
Date:7/3/2008

BIOCITECH, France, July 3 /PRNewswire-FirstCall/ -- Cellectis SA today announced the signature of an agreement with Regeneron Pharmaceuticals, Inc. over the use of Cellectis' patents covering certain uses of homologous recombination for the generation of innovative human therapies, including the development of fully human monoclonal antibodies. As part of the agreement, Cellectis will receive an upfront of 12,450,000$ from Regeneron. In addition, Regeneron will invest in Cellectis' equity.

The agreement resolves a dispute between the two companies related to the interpretation of a license agreement entered into by and between Cellectis and Regeneron in December 2003 pursuant to which Regeneron licensed certain patents and patent applications relating to a process for the specific replacement of a copy of a gene in the receiver genome by homologous recombination. Pursuant to the agreement, Regeneron will make an up-front payment to Cellectis in the amount of $12,450,000. In addition, Regeneron will pay Cellectis a low single-digit royalty based on revenue received by Regeneron from any future licenses or sales of Regeneron's VelociGene(R) or VelocImmune(R) products and services. No royalties are payable with respect to Regeneron's VelocImmune license agreements with AstraZeneca UK Limited and Astellas Pharma Inc. or Regeneron's November 2007 collaboration agreement with sanofi-aventis. Moreover, due to other considerations in the agreement, no royalties are payable on any revenue from commercial sales of antibodies from Regeneron's VelocImmune technology.

Regeneron and Cellectis also entered into a Subscription Agreement pursuant to which Regeneron will acquire 368,301 ordinary shares of Cellectis, par value EUR 0.05 per share, at a price of EUR 8.63 per share, for a total of EUR 3,178,437.63. The subscription is contingent upon the prior approval of the board of directors of Cellectis and by the shareholders of Cellectis at an extraordinary general meeting to be held no later than October 30, 2008.

About the licensed patents:

The agreement relates to Institut Pasteur's patents covering certain uses of homologous recombination (US patents #6 528 313, 6 638 768 and 6 528 314, Japanese patents #3059481, #3298842 and #3298864 and European patents EP #419 621 and #682 112). As the exclusive licensee of these patents, Cellectis has access to the process of targeted integration of DNA sequences.

For further information, please contact:

Cellectis S.A.

David J.D. Sourdive, Ph. D

VP Corporate Development

Tel.: +33-(0)-1-41-83-99-00

e-mail: sourdive@cellectis.com

http://www.cellectis.com

Alize Public Relations

Caroline Carmagnol

Tel.: +33-(0)-6-64-18-99-59

e-mail: caroline@alizerp.com


'/>"/>
SOURCE Cellectis SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
2. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
10. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... San Antonio, Texas (PRWEB) , ... May 23, 2016 , ... The need for blood ... infographic released this week by the South Texas Blood & Tissue Center, blood donations are ... more than 30 years, and they are down 21 percent in South Texas in the ...
(Date:5/23/2016)... Carolina (PRWEB) , ... May 23, 2016 , ... ... and building management solutions and services based in Aurora, Ohio, has broken ground ... established business in the Research Triangle Park area, this new location solidifies a ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical ... Abu Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has ... biomarker discovery studies for preclinical and clinical safety programs. “We’ve seen significant demand ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
Breaking Biology News(10 mins):